Clinical Trial Update: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) [Phase 3]

View source ↗

Summary

Phase 3 EU extension study evaluating subcutaneous immunoglobulin for IgG replacement in patients with primary immunodeficiency; CSL Behring reported results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Sponsor: CSL Behring | Conditions: Primary Immunodeficiency (PID) | Phase 3 | Status: COMPLETED | Results posted: 2013-01-25